1. Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets
   Rong Tan et al, 2025, British Journal of Cancer CrossRef
2. Trifluridine/Tipiracil: An Emerging Strategy for the Management of Gastrointestinal Cancers
   Marc Peeters et al, 2018, Future Oncology CrossRef
3. Trifluridine/Tipiracil Plus Bevacizumab for Third-Line Management of Metastatic Colorectal Cancer: SUNLIGHT Study Design
   Josep Tabernero et al, 2021, Future Oncology CrossRef
4. Quantitative Analysis of the Concentration of Trifluridine in Tumor Hypoxic Regions Using a Novel Platform Combining Functional Endoscopy and Mass Spectrometry
   Shigehiro Koganemaru et al, 2024, Clinical Pharmacology & Therapeutics CrossRef
5. Innovations in colorectal cancer treatment: trifluridine and tipiracil with bevacizumab for improved outcomes – a review
   Taruba Rais et al, 2024, Frontiers in Oncology CrossRef
6. Anticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancer
   Ruohong Lin et al, 2024, Journal of Cancer Research and Clinical Oncology CrossRef
7. Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer
   Kirti K. Iyer et al, 2022, Cancer Treatment Reviews CrossRef
8. Discovery and Development of Trifluridine/Tipiracil (Lonsurf ™)
   Norihiko Suzuki et al, 2018, Successful Drug Discovery CrossRef
9. Further Therapeutic Options in Heavily Pretreated Colorectal Cancer Patients
   Aneta L. Zygulska, 2019, Multidisciplinary Approach for Colorectal Cancer CrossRef
10. Trifluridine / tipiracil (FTd / TPI, TAS-102) in the treatment of patients with metastatic colon cancer: from preclinical experiments to routine clinical practice
    M. Yu. Fedyanin, 2020, Pelvic Surgery and Oncology CrossRef
11. Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status
    Jun Zhang et al, 2024, Oncotarget CrossRef
12. Recent advance in the development of novel, selective and potent FGFR inhibitors
    Feng-Tao Liu et al, 2020, European Journal of Medicinal Chemistry CrossRef
13. Pyrimidine-based anticancer drugs
    Galal H. Elgemeie et al, 2022, New Strategies Targeting Cancer Metabolism CrossRef
14. Extrapolating heterogeneous time-series gene expression data using Sagittarius
    Addie Woicik et al, 2023, Nature Machine Intelligence CrossRef